Table 1.
Main features of reported cases of anaerobic meningitis.
| Author | Bacteria | Methods of identification | Treatment | Type of pathogeny | Outcome | Sex/age (years) |
|---|---|---|---|---|---|---|
| Kalay et al. (4) | Bacteroides fragilis; B. thetaiotaomicron and Fusobacterium necrophorum; Proteus mirabilis. | MALDI-TOF MS; Left ear for culture. |
Vancomycin; Metronidazole; Meropenem; Acyclovir metronidazole | Mastoiditis | Recovery | M/16 |
| Llitjos et al. (18) | Peptostreptococcus micros, Fusobacterium necrophorum, and Porphyromonas gingivalis | 16S rRNA sequencing; standard culture. | Meropenem; Aancomycin; Fosfomycin; Amoxicillin; Metronidazole | NA | Death (47 days) | W/69 |
| Anusha et al. (19) | Bacteroides fragilis | 16S rRNA sequencing; standard culture. | Ceftriaxone; Amoxicillin; Acyclovir | A subdural empyema; Pre-sacral abscess. | Death | M/8-week |
| Yael et al. (12) | Eubacterium multiforme | 16S rRNA sequencing; | Ceftriaxone; Vancomycin; Metronidazole; Ampicillin | Brain penetrating trauma | Neurological sequelae. | M/6 |
| Joshua et al. (27) | Anaerobic gram-negative bacillus. | Blood culture | Benzylpenicillin;Metronidazole; | Rectothecal Fistula Arising from an Anterior Sacral Meningocele | Recovery | M/48 |
| Juan at al. (28) | Bacteroides fragilis, Staphylococcus aureus and Morganella morgagnii | CSF culture | Vancomycin and meropenem | Colorectal surgery | Uneventful outcome | M/68 |